Novo Nordisk A/S is asking for more time to answer questions from US Senator Bernie Sanders on the prices of Ozempic and ...
Sen. Bernie Sanders, chair of the Senate Health, Education, Labor and Pensions Committee, has demanded to know why Americans ...
Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are no true “under-the-radar stocks” in the ...
Building on the continued momentum behind its GLP-1 drugs, the pharma company’s parent company, Novo Holdings, announced a ...
A report from the Kaiser Family Foundation estimates that the FDA’s recent approval of Novo Nordisk’s Wegovy to reduce the risk of heart attack and stroke in people with cardiovascular disease will ...
One of the hottest areas in the pharmaceutical space right now is weight loss. Glucagon-like peptide-1 (GLP-1) medications ...
The two companies, as well as third-party manufacturers, are building huge new facilities to make the ingredients needed for ...
Now, the Federal Trade Commission and its chair, Lina Khan, have voted to ban non-competes citing that the agreements ...
Senator Berne Sanders is launching an investigation into the "outrageously high prices" Novo Nordisk charges for the drugs.
Sen. Bernie Sanders (I-Vt.), chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, launched an ...
But it could wind up costing Medicare nearly $ ... steep increases in spending on GLP-1 drugs. It shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million ...